Pump and dump stocks ... Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for ...

BorgWarner will showcase its latest commercial vehicle (CV) solutions at the Advanced Clean Transportation (ACT) Expo 2025. The company will highlight its comprehensive portfolio of highly efficient ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Amsino has taken a significant step forward in our mission to advance healthcare worldwide. We are proud to announce the establishment of Amsino Scientific Inc., a new medical device manufacturing, ...

A University of Minnesota research team earned a $11.6 million grant to work with the Mayo Clinic on a device designed to ...

The firm’s platform of analytical tools are used in the development of a new class of drugs known as RNA therapeutics – a ...

Medera announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy ...

The biotech is based in Radnor, Pennsylvania and is also one of the 10 Pump and Dump Stocks Favored by Hedge Funds. Mineralys Therapeutics ... while the Advance-HTN trial, conducted with the ...

but has limited disease-modifying therapeutics. SRD-002 is a gene therapy utilizing an adeno-associated type 1 virus vector carrying the cardiac isoform of the sarcoplasmic reticulum calcium ATPase ...

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction ...

Three-dimensional models allow researchers to better represent complex tissues and cell-cell interactions. This article ...